Watchdog says expensive cancer drugs not delivering

Watchdog says expensive cancer drugs not delivering
A study has found that 57 per cent of new cancer drugs in Europe lack clear evidence that they extend or improve patients’ lives Pic: Shutterstock

Value for money criteria met by only one of 20 new drugs that had an initial asking price of €500 million

Just one of 20 new cancer drugs examined by the state’s medicines watchdog was considered value for money, according to a new assessment by the body.

Professor Michael Barry, who heads up the National Centre for Pharmacoeoconomics (NCPE), said the assessment of cancer drugs raised “obvious questions” around how we decided to spend limited resources in the health service.

“The question has to be asked - would we be better spending such millions elsewhere in...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post